Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05801978 · ClinicalTrials.gov registry record · Phase 4
Durability of Vaccine Responses
A Phase 4 study of Vaccine Response, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 66
- Enrollment target
- 3
- Study locations
NCT05801978 is a Phase 4 study of Vaccine Response that is actively recruiting participants, run by Emory University. The registered enrollment target is 66 participants. The trial reports 3 study locations across 1 state.
The verdict
NCT05801978, a Phase 4 study of Vaccine Response, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 66 participants
- Enrollment target
- 3
- Study locations
Study Summary
The ability of the vaccines today to generate a long-lasting protection against infections varies greatly from one vaccine to another. The yellow fever vaccine (YF-17D) is one of the most successful vaccines ever developed, having been administered to over 600 million people globally. A single vaccination is known to induce durable protection over several decades. In contrast, the quadrivalent influenza vaccine (QIV) generates an immunity that wanes quickly with no long-lasting protection. Currently, the duration of immune protection for new vaccines is difficult to predict during vaccine product development and can only be ascertained by a "wait and see" approach. This is due, in part, to the fact that some of the signals that activate a durable immune system protection remain unknown. This study aims to provide a better understanding of this problem by vaccinating willing participants with either the FDA-approved yellow fever vaccine or the quadrivalent influenza vaccine and collecting baseline and follow-up biologic samples to compare how the immune system reacts.
Conditions Studied
Interventions
- BIOLOGICAL Live Attenuated Yellow Fever 17D Vaccine
- BIOLOGICAL Quadrivalent seasonal influenza vaccine
Study Locations (3)
Georgia
- Emory University Hospital - Atlanta
- Emory Winship Cancer Institute - Atlanta
- The Hope Clinic of Emory University - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-04-11 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05801978
The ClinicalTrials.gov registry entry for NCT05801978 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Vaccine Response appearing as the primary indexed condition, and to 2 interventions - of which Live Attenuated Yellow Fever 17D Vaccine is the first listed.
NCT05801978 reports 3 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT05801978 about?
NCT05801978 is a clinical study titled "Durability of Vaccine Responses". The ability of the vaccines today to generate a long-lasting protection against infections varies greatly from one vaccine to another. The yellow fever vaccine (YF-17D) is one of the most successful vaccines ever developed, having been administered to over 600 million people globally. A single vacci...
What is the current status of trial NCT05801978?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 66 participants. The study started on 2023-04-11. Estimated completion is 2026-09-30.
What conditions does trial NCT05801978 study?
This clinical trial studies the following conditions: Vaccine Response.
What interventions are being tested in trial NCT05801978?
The interventions under investigation include: Live Attenuated Yellow Fever 17D Vaccine (BIOLOGICAL), Quadrivalent seasonal influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05801978?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05801978 being conducted?
This trial has 3 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vaccine Response
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.